Laureus Capital

ETHRIS develops mRNA therapeutics with a focus on respiratory diseases and vaccines. ETHRIS possesses an enabling LNP delivery and mRNA modification platform for transcript Therapies. SNIM®RNAis a first-in-class biopharmaceutical which provide a compelling alternative for recombinant protein or gene therapies. SNIM®RNAs encode therapeutic proteins to be produced in the patient‘s body and overcome short duration effects of recombinant proteins. SNIM®RNA Transcript Therapy is a new option for a broad variety of diseases, either acquired or genetically predetermined, lifestyle- or age-related, rare or frequent.

Impossible Cloud is the first decentralized, enterprise-grade cloud platform that utilizes web3 technology to offer businesses faster, cheaper, and more secure multi-service cloud solutions at a fraction of the cost compared to hyperscalers and on-premises private clouds. Its comprehensive suite of services is backed by a fiat-based payment system and business model catering to B2B customers, without the need to transact with tokens or cryptocurrency. ​​ ​Impossible Cloud’s decentralized architecture is designed for 100% durability and availability, and supports an almost unlimited capacity of storage with no hidden costs. Additionally, it can provide access to a global network of enterprise-grade storage hubs, enabling reliable performance and efficiency near the customer’s edge.